Considerations and Challenges Surrounding CAR-T Therapy and Bispecifics

Among 18 patients with central nervous system lymphoma treated with the ibrutinib/nivolumab combination regimen, 3 had remission beyond 2 years.

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

Anaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Support for the decision follows a positive opinion from the Committee for Medicinal Products for Human Use based on the phase 3 ECHO trial results.

Results from the phase 3 HD21 trial showed that brentuximab vedotin plus chemotherapy was superior to alternative treatments in Hodgkin lymphoma.